Abstract: The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.

Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.

Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Abstract: The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids. Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.

Abstract: A method and system are provided for updating a dual layer browser which displays a hierarchy of nodes. The method or system provides a first layer or “browser provider” which receives various changed data notifications, determines which changed data notifications affect the current browser display, and sends the required notifications to a second layer or “browser.” The browser then makes the necessary adjustments to the current display.

Abstract: A method for depicting data on the display of a modular display unit is provided. The data to be depicted comprises safety-critical data portions and non-safety-critical data portions data stream and depicted on the display via a graphical to the invention, a safety component of the display unit generates the safety-critical data portions based on safety-critical signals which are supplied to the display unit, while a background component of the display unit generates the non-safety-critical data portions in the form of a background screen. The safety-critical data portions are put on the display over said background screen in that a multiplexer converts the graphical data stream for display between the safety component and the background component, wherein, the specific regions, graphical content of the background screen changes and safety-critical graphical content is introduced and depicted on the display.

Abstract: An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: a light-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No1 such as defined in the description, and a heavy-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No2 such as defined in the description, characterized in that it consists of an IgG1 or an IgG2.

Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.

Abstract: A system and method are provided for instantiating tools within a computer application. The method includes defining a base class, base methods and base properties, wherein the base methods and base properties are associated with the base class. The method includes defining a tool class inheriting from the base class, wherein the tool class will include the base methods and properties. The method includes instantiating a first tool from the tool class within the computer application, wherein the computer application automates human resource management processes. The method includes providing the first tool within the computer application, wherein the first tool provides a user interface to a functionality of the computer application.

Abstract: A system and method are provided for handling different types of objects within a software framework. In an embodiment, an object handler keeps track of information associated with objects, and information needed to implement a user interface. The software framework employing the object handler uses that information to create the user interface so as to get user input/action. A user may select an object type and enter an associated one or more identifiers via the user interface. In response to the entering of the information, a method call of the object handler is made to determine whether the object associated with the object type and identifiers exists, and depending upon that determination, an action or further method call may be initiated and/or requested.

Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Abstract: Methods and systems for verifying module codes are presented. The module code may be verified by associating the module code with a user interface screen and determining whether the module code was generated from the user interface screen. A module corresponding to the module code may be executed if the module code is verified. The module code may be verified by using routines from a user interface framework system. The module code may be verified by determining whether a user interface element associated with the module code is disabled. The module code may be verified by determining whether each user interface element associated with the module code is enabled. The module code may be verified by insuring that the module code was generated by the selection of a user interface element. The module codes may be received from a front-end system and verified on a back-end system.

Abstract: A system and method are provided for stacking global variables associated with a plurality of tools. The method includes loading a first tool global variable into a memory and executing a first tool of a computer application, the computer application configured to automate human resource processes. The method includes responsive to a call to execute a second tool of the computer application, pushing the first tool global variable onto a stack. The method includes loading a second tool global variable into the memory and executing the second tool. The method includes responsive to completing execution of the second tool, popping the first tool global variable off the stack and loading the first tool global variable back into the memory.

Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.

Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.

Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analyses, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.

Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.